Current Options and Future Directions in Castrate Resistant Prostate (CRPC) by Suzanne Richter & Srikala S. Sridhar
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Current Options and  
Future Directions in Castrate  
Resistant Prostate (CRPC) 
Suzanne Richter and Srikala S. Sridhar  
Department of Medical Oncology, Princess Margaret Hospital 
University of Toronto 
Canada 
1. Introduction 
Prostate cancer is the most frequently diagnosed malignancy in North America and second 
leading cause of cancer-related death (Jemal et al., 2010). Despite effective local therapy, 
prostate cancer often recurs. Standard therapy for recurrent or metastatic prostate cancer 
remains androgen deprivation therapy (ADT) which is highly effective but not durable 
(Sharifi et al., 2005). All patients will eventually progress to castrate resistant prostate cancer 
(CRPC) where there are few treatment options and until recently survival was a dismal 12-
18 months (Tannock et al., 1996). In this chapter we will review the current treatment 
approaches for CRPC, but focus primarily on the newly approved options available in the 
post-docetaxel setting. 
Castrate-resistant prostate cancer (CRPC) is defined as prostate cancer progression 
despite ADT and may present with either increasing serum prostate-specific antigen 
(PSA) levels, radiologic progression, and/or the appearance of new metastases (Saad and 
Hotte, 2010). Over the years, advanced prostate cancer has been referred to as hormone-
resistant prostate cancer (HRPC) or androgen-insensitive prostate cancer (AIPC), but the 
name has changed to CRPC to reflect the fact that intracrine/paracrine androgen 
production and signaling pathways play an important role in mediating resistance to first 
line ADT. CRPC presents as a spectrum of diseases ranging from patients with rising PSA 
alone, without metastases or symptoms to patients with rising PSA, progressive 
metastatic disease and significant symptoms. In patients who develop CRPC and who are 
relatively asymptomatic, secondary hormonal treatments may be attempted. To date, no 
study of secondary hormone treatment has demonstrated survival benefits, but most trials 
have been small, underpowered and confounded by the use of subsequent treatments. In 
patients who are progressing on ADT, discontinuation of antiandrogens, introduction of 
low dose prednisone or ketoconazole to block production of adrenal androgens, can offer 
transient PSA responses and palliative benefits in 30% to 35% of patients (Storlie et al., 
1995; Small et al., 2004; Heng and Chi, 2006). 
For CRPC patients with symptoms, rapid PSA progression or visceral disease, docetaxel 
chemotherapy and prednisone is currently considered standard of care. Docetaxel is a 
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member of the taxane family of drugs which binds to tubulin and causes microtubule 
stabilization, leading to cell cycle arrest in the G2/M phase and subsequently cell death 
(Jordan et al., 1993). Docetaxel is adminstered every three weeks intravenously at a dose of 
75mg/m2 with oral prednisone 5 mg twice daily. This is based on two pivotal randomized 
phase III trials, the TAX 327 trial and the SWOG 9916 trial. TAX 327 randomized more than 
1000 patients to receive docetaxel plus prednisone (weekly or every 3 weeks) or 
mitoxantrone plus prednisone (the previous first-line option). The every 3 week docetaxel 
arm had a median survival of 18.9 months compared with 16.5 months in the mitoxantrone 
arm. PSA response rates (defined as  50% drop in serum PSA level) were 48% in the 
docetaxel group and 32% in the mitoxantrone arm (Tannock et al., 2004). In the SWOG 9916 
study, 770 patients were randomized to receive either docetaxel plus estramustine and 
prednisone or mitoxantrone plus prednisone. Again the median overall survival was longer 
(17.5 months vs. 15.6 months, P=0.02 by the log-rank test) and PSA response rates were 
higher (50% vs. 27%, P<0.001) with docetaxel compared with mitoxantrone (Petrylak et al., 
2004). Given the efficacy of docetaxel as a single agent and potential thromboembolic 
toxicity from the addition of estramustine, docetaxel alone with daily prednisone became 
the standard approach. Although in the trial setting, patients received up to 10 cycles of 
treatment, in routine practice where patients are less fit, an average of 7 cycles is the length 
of treatment (Chin et al., 2010). Some patients also appear to respond to retreatment with 
docetaxel, raising the concept of docetaxel refractory vs. docetaxel resistant disease (Chin et 
al., 2010). Nonetheless, all patients will eventually develop taxane resistance and progress. 
In the second line setting, mitoxantrone chemotherapy has palliative benefits, but does not 
offer a survival advantage, underscoring the need for new strategies in the post-docetaxel 
setting (Tannock et al., 1996). 
Much of the research in the post-docetaxel setting has focused on understanding taxane 
resistance. Several mechanisms have been proposed including alterations in both 
docetaxel uptake and retention in cells; changes to tubulin affecting binding sites for 
docetaxel; and changes in the androgen receptor (AR), which may also contribute in part 
to the anticancer activity of docetaxel (Gan and Kavallaris, 2008; Seruga et al., 2010). 
Strategies aimed at overcoming taxane resistance may extend the therapeutic benefit of 
the taxanes in CRPC. 
2. Cabazitaxel 
Cabazitaxel is a new semi-synthetic derivative of the taxoid 10-deacetylbaccatin-III, which 
like docetaxel binds to and stabilizes tubulin. But, unlike docetaxel is a poor substrate for the 
P-glycoprotein drug efflux pump and may also have enhanced penetration through the 
blood-brain barrier (Niraula and Tannock, 2011). In a Phase 1 trial of cabazitaxel the dose 
limiting toxicity at 25 mg/m2 every 3 weeks was grade 4 neutropenia, and the common 
non-hematologic adverse events included low grade diarrhea (52%), nausea (40%) and 
vomiting (16%). Two patients with CRPC, including one previously treated with docetaxel 
showed a partial response (Mita et al., 2009). 
A phase III multicenter, multinational trial comparing cabazitaxel with mitoxantrone in 
the second line setting was conducted with a primary endpoint of overall survival (OS) 
(de Bono, 2010). Cabazitaxel significantly improved median OS compared with 
mitoxantrone (15.1 months vs 12.7 months, respectively; HR 0.72; 95% CI 0.61-0.84; 
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p<0.0001). Secondary endpoints including progression free survival (PFS) (2.8 months vs 
1.4 months), response rate (14.4% vs 4.4%; p=0.005), and median time to progression 
(TTP) by tumor assessment (8.8 months vs. 5.4 months; p<0.0001) also favored cabazitaxel. 
From a toxicity standpoint febrile neutropenia, neutropenia, leukopenia and diarrhea 
were more common in the cabazitaxel arm. One major concern with cabazitaxel however 
was a toxic death rate of 5% compared to only 1.9% for mitoxantrone. As cabazitaxel 
moves out of the controlled clinical trial setting into general use, early and proactive 
management of the toxicites will be critical. Cabazitaxel was FDA approved in 2010 for 
patients progressing on or after docetaxel. In the same year, a second drug, Abiraterone 
was also approved for use in the post-docetaxel setting. 
3. Abiraterone 
Over the last decade there has been a paradigm shift in the approach to CRPC, where 
despite castrate testosterone levels, there appears to be continued androgen receptor 
expression and signaling, suggesting that the androgen receptor axis is still a rational 
therapeutic target. In CRPC, androgens are mainly produced by the adrenal glands and by 
the prostate cancer cells themselves. This occurs by the sequential conversion of cholesterol 
to dihydrotestosterone and testosterone. This conversion is mediated by the CYP17 enzyme, 
which when inhibited can block androgen production. Ketoconazole, an antifungal agent, 
was the first generation CYP17 inhibitor that was tested in prostate cancer, with some 
benefit, but to date no studies have confirmed a survival benefit. On the other hand, 
abiraterone acetate (abiraterone), an oral, irreversible and more selective inhibitor of CYP17 
has shown very encouraging results in the post-docetaxel setting. 
In Phase I/II testing of abiraterone, there were no dose limiting toxicities, the main side 
effects were hypokalemia and lower-limb edema (due to the mineralocorticoid excess from 
the upstream inhibition of 17 alpha-hydroxylase), and antitumor activity was seen at all 
dose levels (Ryan et al., 2010). A Phase III double blind, randomized, placebo-controlled trial 
of abiraterone 1000 mg daily plus prednisone (to avoid the mineralocorticoid related effects) 
versus prednisone alone, with the primary endpoint of OS was initiated (de Bono et al., 
2011). In total, 1,195 post-docetaxel CRPC patients were accrued, and treated until clinical or 
radiographic disease progression. Of note, biochemical progression alone (rising PSA) was 
not considered sufficient for discontinuation of the study drug. Interim analysis 
demonstrated increased median OS in the abiraterone arm, at 14.8 months compared to 10.9 
months (HR 0.65, 95% CI 0.54-0.77) for prednisone leading to early termination of the trial. 
Other key endpoints including PSA response, time to PSA progression and radiographic 
progression free survival were all significantly improved in the abiraterone arm. Time to 
skeletal related events (SRE), defined as pathologic fracture, spinal cord compression, or 
palliative radiation therapy or surgery also favored the abiraterone arm. Mineralocorticoid 
related adverse events, consisting of hypertension and hypokalemia were more common in 
the abiraterone arm, but grade 3+ events were infrequent. A second Phase III trial of 
abiraterone in the pre-docetaxel setting has closed to accrual and results will likely be 
available in 2012. 
Since both abiraterone and cabazitaxel are now approved in the post-docetaxel setting, a 
key question will be to determine the optimal sequencing of these agents. At this point it 
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will likely be done on a case by case basis after careful consideration of the rate of 
disease progression, overall burden of disease, performance status and toxicity profile of 
either drug. 
4. Sipuleucel-T 
Aside from cytotoxic therapies and androgen deprivation approaches, immunotherapy has 
emerged in prostate cancer drug development. Sipuleucel-T (Provenge, Dendreon) is an 
immunotherapy that can enhance response to the prostate cell tumor antigen, prostatic acid 
phosphatase. Generation of the immunotherapy involves collection of peripheral blood cells 
by leukophoresis and subsequent exposure to prostatic acid phosphatase and granulocyte 
macrophase colony stimulating growth factor. The cells are then reintroduced into the 
patient. Sipuleucel-T is an autologous dendritic cell vaccine which enhances prostatic acid 
phosphatase related T cell response. 
Encouraging phase I/II trial results led to the pivotal randomized, double-blind, placebo-
controlled, multicenter trial (Study 9902B) known as the IMPACT trial (Immunotherapy for 
Prostate Adenocarcinoma Treatment), with a primary endpoint of overall survival (Kantoff 
et al., 2010). All patients underwent three leukapheresis procedures (Weeks 0, 2, and 4), 
followed 3 days later by either sipuleucel-T or the non-activated control. Eligible CRPC 
patients had metastatic disease in soft tissue and/or bone with evidence of radiologic or 
biochemical disease progression. Patients with moderate to severe prostate cancer-related 
pain and/or use of narcotics were excluded. Tumor expression of prostatic acid phosphatase 
of 25% or more was required. Five hundred twelve patients were randomized (2:1) to 
sipuleucel-T (n=341) or control (n=171). The sipuleucel-T arm had a 4.l months 
improvement in median overall survival (25.8 mos versus 21.7 mo, p= 0.032, HR 0.775, 95% 
CI 0.61, 0.98). There was no difference in time-to-progression. Common adverse events (AE) 
for sipuleucel-T were mild or moderate and included chills, fatigue, fever, back pain, 
nausea, joint ache and headache. Serious adverse reactions (SAE) more common with 
sipuleucel-T were acute infusion reactions and stroke. Similar survival and tolerability 
results were seen in two additional trials, which ultimately led to approval by the US Food 
and Drug Administration in 2010 (Small et al., 2006; Higano et al., 2009). Priced at $31,000 per 
treatment, Sipuleucel-T is one of the most expensive treatments ever, and as such may not 
be as widely available as either abiraterone or cabazitaxel. 
5. Zoledronic acid 
Over the last 10 years, there has also been growing interest in the issue of bone health in 
prostate cancer as it is known that both androgen deprivation therapy, and bony metastases 
can promote bone destruction. Zoledronic acid, is a nitrogen-containing bisphosphonate 
that inhibits osteoclast-mediated bone resorption. In a randomized placebo controlled 
clinical trial in men with CRPC and bone metastases, zoledronic acid reduced skeletal 
related events and decreased bone pain leading to its approval by the FDA in 2002 (Saad et 
al., 2002). Bone resorption is a process that is dependent on RANK Ligand, a protein that 
acts as the primary mediator of osteoclast formation, function and survival. Preclinical 
models have demonstrated that inhibiting RANK Ligand significantly improves cortical and 
trabecular bone density, volume and strength. Studies with a novel bone targeting agent 
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known as Denosumab have been encouraging, and offers another agent to address the bone 
complications of prostate cancer. 
6. Denosumab 
Denosumab is a fully humanized monoclonal antibody against the RANK ligand. RANK 
plays a major role in osteoclast activation. In the phase III trial of 1901 CRPC patients with 
one or more metastases, compared to zoledronic acid, denosumab delayed time to skeletal 
related events by approximately 3 months with a 2.3% incidence of osteonecrosis of the jaw 
compared to 1.3% in the zoledronic acid arm. Notably, there was no difference in overall 
survival (Fizazi et al., 2011). This phase III study garnered FDA approval for Denosumab for 
the prevention of skeletal related events (SRE) in CRPC patients with bone metastases. 
Denosumab is also being evaluated for its ability to delay the development of bone 
metastases in CRPC patients. A third role for denosumab may be in protecting against ADT 
related osteoporosis. In this study, 912 patients on ADT received denosumab 60 mg 
subcutaneously every 6 months. At 24 months followup, denosumab was associated with 
increased bone mineral density at all sites and a reduction in the incidence of new vertebral 
fractures (Smith et al., 2009). Denosumab also offers the benefit of being subcutaneously 
administered, and this might be an advantage for patients who are not otherwise requiring 
intravenous treatments. 
7. Summary 
There has been a significant increase in the number of treatment options available to men 
with CRPC. These advancements have included therapies with new taxane derivatives, 
drugs targeting the androgen axis, immunotherapy and bone targeting agents. 
Cabazitaxel, abiraterone and sipuleucel-T all show survival benefits, while Denosumab 
appears to reduce the risk of new bone metastases and skeletal related events in CRPC 
patient with bone metastases. But, with these new options comes new questions, such as, 
what is the optimal sequencing of these agents. As sequencing strategies become 
increasingly common, comparison of survival against historic data in addition to 
comparison of outcomes between newer agents and their associated trials will become 
increasing difficult to analyze. Whether results in the post docetaxel setting will be 
replicated in the chemonaive prostate cancer population awaits further definition. Also it 
is unclear if any of these agents will work better in combination with each other or with 
other molecular targeted therapies, although to date the latter have been disappointing in 
prostate cancer. What is very exciting however, is the fact that through drug development 
new information has become available enhancing our understanding of tumor 
progression in prostate cancer. Future areas of exploration include the use of newer 
agents in the prechemotherapy and neoadjuvant setting, using objective biologic 
endpoints such as pathologic response and radiographic response over short treatment 
intervals. Defining new endpoints may assist in circumventing the eventual difficulty in 
proceeding with large trials of heterogeneous patients in whom a placebo controlled trial 
design may not be feasible. Lastly, as the understanding of the molecular drivers of 
disease progression become increasingly understood, molecular markers that may serve 
as surrogate clinical trial endpoints may emerge, further enhancing a flourishing field. 
www.intechopen.com
 




Chin, S.N., Wang, L., Moore, M., and Sridhar, S.S. (2010) A review of the patterns of 
docetaxel use for hormone-resistant prostate cancer at the princess margaret 
hospital. Curr Oncol, 17, 24-9. 
de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K.N., Jones, R.J., 
Goodman, O.B., Jr., Saad, F., Staffurth, J.N., Mainwaring, P., Harland, S., Flaig, 
T.W., Hutson, T.E., Cheng, T., Patterson, H., Hainsworth, J.D., Ryan, C.J., Sternberg, 
C.N., Ellard, S.L., Flechon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., 
Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C.M., and Scher, H.I. (2011) 
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364, 
1995-2005. 
de Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.P., Kocak, I., Gravis, G., 
Bodrogi, I., Mackenzie, M.J., Shen, L., Roessner, M., Gupta, S., and Sartor, A.O. 
(2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-
resistant prostate cancer progressing after docetaxel treatment: A randomised 
open-label trial. Lancet, 376, 1147-54. 
Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., 
Rader, M., Wang, H., Jiang, Q., Tadros, S., Dansey, R., and Goessl, C. (2011) 
Denosumab versus zoledronic acid for treatment of bone metastases in men with 
castration-resistant prostate cancer: A randomised, double-blind study. Lancet, 377, 
813-22. 
Gan, P.P., and Kavallaris, M. (2008) Tubulin-targeted drug action: Functional significance 
of class ii and class ivb beta-tubulin in vinca alkaloid sensitivity. Cancer Res, 68, 
9817-24. 
Heng, D.Y., and Chi, K.N. (2006) Prednisone monotherapy in asymptomatic hormone 
refractory prostate cancer. Can J Urol, 13, 3335-9. 
Higano, C.S., Schellhammer, P.F., Small, E.J., Burch, P.A., Nemunaitis, J., Yuh, L., Provost, 
N., and Frohlich, M.W. (2009) Integrated data from 2 randomized, double-blind, 
placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-
t in advanced prostate cancer. Cancer, 115, 3670-9. 
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2010) Global cancer 
statistics. CA Cancer J Clin, 61, 69-90. 
Jordan, M.A., Toso, R.J., Thrower, D., and Wilson, L. (1993) Mechanism of mitotic block and 
inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S 
A, 90, 9552-6. 
Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, 
C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., Xu, Y., Frohlich, M.W., and 
Schellhammer, P.F. (2010) Sipuleucel-t immunotherapy for castration-resistant 
prostate cancer. N Engl J Med, 363, 411-22. 
Mita, A.C., Denis, L.J., Rowinsky, E.K., Debono, J.S., Goetz, A.D., Ochoa, L., Forouzesh, B., 
Beeram, M., Patnaik, A., Molpus, K., Semiond, D., Besenval, M., and Tolcher, A.W. 
(2009) Phase i and pharmacokinetic study of xrp6258 (rpr 116258a), a novel taxane, 
administered as a 1-hour infusion every 3 weeks in patients with advanced solid 
tumors. Clin Cancer Res, 15, 723-30. 
www.intechopen.com
 
Current Options and Future Directions in Castrate Resistant Prostate (CRPC) 
 
269 
Niraula, S., and Tannock, I.F. (2011) Broadening horizons in medical management of 
prostate cancer. Acta Oncol, 50 Suppl 1, 141-7. 
Petrylak, D.P., Tangen, C.M., Hussain, M.H., Lara, P.N., Jr., Jones, J.A., Taplin, M.E., Burch, 
P.A., Berry, D., Moinpour, C., Kohli, M., Benson, M.C., Small, E.J., Raghavan, D., 
and Crawford, E.D. (2004) Docetaxel and estramustine compared with 
mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J 
Med, 351, 1513-20. 
Ryan, C.J., Smith, M.R., Fong, L., Rosenberg, J.E., Kantoff, P., Raynaud, F., Martins, V., Lee, 
G., Kheoh, T., Kim, J., Molina, A., and Small, E.J. (2010) Phase i clinical trial of the 
cyp17 inhibitor abiraterone acetate demonstrating clinical activity in patients with 
castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin 
Oncol, 28, 1481-8. 
Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J.L., 
Vinholes, J.J., Goas, J.A., and Chen, B. (2002) A randomized, placebo-controlled trial 
of zoledronic acid in patients with hormone-refractory metastatic prostate 
carcinoma. J Natl Cancer Inst, 94, 1458-68. 
Saad, F., and Hotte, S.J. (2010) Guidelines for the management of castrate-resistant prostate 
cancer. Can Urol Assoc J, 4, 380-4. 
Seruga, B., Ocana, A., and Tannock, I.F. (2010) Drug resistance in metastatic castration-
resistant prostate cancer. Nat Rev Clin Oncol, 8, 12-23. 
Sharifi, N., Gulley, J.L., and Dahut, W.L. (2005) Androgen deprivation therapy for prostate 
cancer. Jama, 294, 238-44. 
Small, E.J., Halabi, S., Dawson, N.A., Stadler, W.M., Rini, B.I., Picus, J., Gable, P., Torti, F.M., 
Kaplan, E., and Vogelzang, N.J. (2004) Antiandrogen withdrawal alone or in 
combination with ketoconazole in androgen-independent prostate cancer patients: 
A phase iii trial (calgb 9583). J Clin Oncol, 22, 1025-33. 
Small, E.J., Schellhammer, P.F., Higano, C.S., Redfern, C.H., Nemunaitis, J.J., Valone, F.H., 
Verjee, S.S., Jones, L.A., and Hershberg, R.M. (2006) Placebo-controlled phase iii 
trial of immunologic therapy with sipuleucel-t (apc8015) in patients with 
metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol, 24, 
3089-94. 
Smith, M.R., Egerdie, B., Hernandez Toriz, N., Feldman, R., Tammela, T.L., Saad, F., 
Heracek, J., Szwedowski, M., Ke, C., Kupic, A., Leder, B.Z., and Goessl, C. (2009) 
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N 
Engl J Med, 361, 745-55. 
Storlie, J.A., Buckner, J.C., Wiseman, G.A., Burch, P.A., Hartmann, L.C., and Richardson, 
R.L. (1995) Prostate specific antigen levels and clinical response to low dose 
dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer, 76, 
96-100. 
Tannock, I.F., de Wit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N., Oudard, S., 
Theodore, C., James, N.D., Turesson, I., Rosenthal, M.A., and Eisenberger, M.A. 
(2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced 
prostate cancer. N Engl J Med, 351, 1502-12. 
www.intechopen.com
 
Prostate Cancer – Diagnostic and Therapeutic Advances 
 
270 
Tannock, I.F., Osoba, D., Stockler, M.R., Ernst, D.S., Neville, A.J., Moore, M.J., Armitage, 
G.R., Wilson, J.J., Venner, P.M., Coppin, C.M., and Murphy, K.C. (1996) 
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for 
symptomatic hormone-resistant prostate cancer: A canadian randomized trial with 
palliative end points. J Clin Oncol, 14, 1756-64. 
www.intechopen.com
Prostate Cancer - Diagnostic and Therapeutic Advances
Edited by Dr. Philippe E. Spiess
ISBN 978-953-307-319-4
Hard cover, 378 pages
Publisher InTech
Published online 25, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
In this book entitled "Prostate Cancer - Diagnostic and Therapeutic Advances", we highlight many of the
significant advances made in our treatment armamentarium of prostate cancer. The book is subdivided into
four sections termed: 1) novel diagnostic approaches, 2) surgical treatments options, 3) radiation therapy and
its potential sequelae, and 4) medical management and its treatment complications. After reading the present
book , readers will be very familiar with the major clinical advances made in our multifaceted treatment
approach to prostate cancer over the past decade.This book is a tribute to our pioneering urologists and allied
healthcare professionals who have continually pushed forward our traditional therapeutic envelope.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Suzanne Richter and Srikala S. Sridhar (2011). Current Options and Future Directions in Castrate Resistant
Prostate (CRPC), Prostate Cancer - Diagnostic and Therapeutic Advances, Dr. Philippe E. Spiess (Ed.), ISBN:
978-953-307-319-4, InTech, Available from: http://www.intechopen.com/books/prostate-cancer-diagnostic-
and-therapeutic-advances/current-options-and-future-directions-in-castrate-resistant-prostate-crpc-
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
